Insights

Although there's very little evidence of a housing supply glut, the best opportunities for property investors are not in high-density dwellings.

The sudden and unexpected discounting of US ETFs on August 24 has prompted questions about the unintended side effects of new laws brought in after the 2010 flash crash.

Market nerves could intensify if a concerted rally is delayed. Trend followers who aim to stay on the right side of the market's medium to long term direction are now in cash.

We profile a fund manager who is focusing on growth stocks and getting excited about the shift from bricks and mortar to online.

For superannuants fearful that a Labor Government would tax super earnings above $75,000, equalising spouses' balances may be an option.

This week we look at Macquarie, Woodside, Oil Search and Sigma Pharmaceutical.

Santos, investing in Japan and Dick Smith.

It's all about the Fed now with opinion divided about whether it will announce an increase in US interest rates at 4am AEST on Friday. Last night's US market moves appeared to be a logical response to the possibility that the Fed will begin the gradual process of lifting interest rates this week.

Falling international share prices and lower commodities dominated any positives from Prime Ministerial renewal in the opening hours of trading in Australia today.

Hotly watched Chinese stats say the economy is in trouble but the actions of consumers tell a different story.

Don't miss prominent investor and Thorney Opportunities chairman Alex Waislitz, while Milton Corporation managing director Frank Gooch will take your questions.

True to George Soros's maxim, AFI's investing style might be boring, but it has served the company and its investors well through eight decades of tumultous markets. While it may not be as exciting as the newcomers, it has a compelling offering for investors.

In the absence of a crisis, it's not likely the local currency will trade at US60c or below for any length of time.

The automotive group has bought its larger competitor in a mutually beneficial deal.

The IT services and consulting business offers an attractive yield and appears set to benefit from a recovery in demand.

Attracted by the economics of genomics, investors have driven up the price of market leader Illumina in the last two years, but recent market falls have provided a buying opportunity.